Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab

INTRODUCTION: Given the varying severity of coronavirus disease 2019 (COVID-19) and the rapid spread of Severe-Acute-Respiratory-Syndrome-Corona-Virus-2 (SARS-CoV-2), vaccine-mediated protection of particularly vulnerable individuals has gained increasing attention during the course of the pandemic....

Descripción completa

Detalles Bibliográficos
Autores principales: Räuber, Saskia, Willison, Alice, Korsen, Melanie, Kölsche, Tristan, Golombeck, Kristin S., Plaack, Benedikt, Schüller, Julia, Huntemann, Niklas, Rolfes, Leoni, Schroeter, Christina B., Nelke, Christopher, Regner-Nelke, Liesa, Förster, Moritz, Ringelstein, Marius, Barnett, Michael Harry, Hartung, Hans-Peter, Aktas, Orhan, Albrecht, Philipp, Ruck, Tobias, Melzer, Nico, Meuth, Sven G., Kremer, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822773/
https://www.ncbi.nlm.nih.gov/pubmed/36618356
http://dx.doi.org/10.3389/fimmu.2022.1037214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822773/
https://www.ncbi.nlm.nih.gov/pubmed/36618356
http://dx.doi.org/10.3389/fimmu.2022.1037214

Ejemplares similares